Most growth stocks have struggled in early 2025. Despite this volatility, several innovators continue to post strong ...

Despite this recent downturn, AVGO stock has achieved considerable long-term growth, rising over 300% since the beginning of ...

Avoiding the Magnificent Seven has helped some managers outperform rivals for the first time in years.

After the dust has settled, some investors could be forgiven for not knowing what is the upshot of the new tariff agreement between China and the U.S.. While the terms are not as bad as feared, ...

Palantir's Q1 2025 earnings report showed solid performance despite seasonal challenges, with U.S. commercial growth at 19.2% ...

Two biotech stocks make perfect candidates for this sort of strategy right now. Let's take a close look at these two biotech ...

UnitedHealth Group Incorporated stock drops after a rare earnings miss and CEO resignation. Click for the impact and ...

Despite how volatile it has been along the way, it's impossible to deny Tesla's (NASDAQ: TSLA) long-term share price ...

UnitedHealth stock tumbled in premarket trading on Tuesday after suspending its 2025 outlook and announcing Stephen Hemsley's ...

Considering a 100% stock portfolio for retirement? Learn the benefits and risks to determine if this aggressive strategy ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Amplitude had a promising public offering, but the stock mostly struggled since 2022. After the recent acquisition, the company has finalized its platform, making its analytics software more ...